Utilising Biomarkers to Eliminate Drug Candidates with Cardiotoxicity in Preclinical Development By Dr Federica Crivellente The rapidly escalating costs of drug development is causing the biopharmaceutical industry to focus its R&D efforts on identifying new technologies and methods that can predict the safety and efficacy of new compounds as early as possible in the drug […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!